The Top 5 Biosimilars Articles for the Week of September 3
The Center for Biosimilars® recaps the top news for the week of September 3, 2018.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 3.
Number 5: A newly published study in pediatric patients with Crohn disease found that infliximab improved clinical outcome measures from week 2 to week 56.
Number 4: New Zealand’s cost control agency has proposed to stop funding Janssen’s epoetin alfa in favor of funding Novartis’ biosimilar.
Number 3: New research shows that patients may be paying more out of pocket for biosimilar infliximab, and that the advent of biosimilar filgrastim has not expanded access.
Number 2: Celltrion is asking the United Kingdom to lower its threshold to provide access to biologic drugs for patients with rheumatoid arthritis.
Number 1: The FDA heard from 27 speakers, from across the spectrum of stakeholders, at its public hearing on the Biosimilar Action Plan.
Finally, last week, our e-newsletter asked whether you think that the FDA should do away with its current guidance on biosimilar suffixes.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
